- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02474888
Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis (MONITUX)
Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis : a Predictive Factor of Clinical Outcome? (MONITUX)
The aim of the investigators' study is to evaluate whether monitoring serum rituximab levels could be an interesting tool in the follow-up of ANCA-associated vasculitis patients.
All consecutive patients, hospitalized for a new diagnosis of ANCA-associated vasculitis or the relapse of a known ANCA-associated vasculitis, in which the decision to start an induction regimen with rituximab has been taken, will be included.
Serum rituximab levels (along with serum anti-rituximab antibodies levels) will be determined (at M+1 and M+3) and the correlation with clinical outcome at M+6 will be analyzed.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69003
- Hôpital Edouard Herriot
-
Lyon, France, 69317
- Hôpital de La Croix Rousse
-
Pierre-Bénite, France, 69495
- CH Lyon sud
-
Saint-Etienne, France, 42055
- Chu Saint-Etienne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 18 years
- Granulomatosis with polyangiitis or microscopic polyangiitis (according to Chapel Hill criterions), with or without detectable ANCA
- Decision taken to start an induction regimen with rituximab
- Informed and having signed the study consent form
- If of child-bearing potential, female patients will have use an effective method of contraception during RTX (rituximab) treatment and in the 12 months following RTX treatment stop
- no-breast-feeding during RTX treatment and in the 12 months following RTX treatment stop
Exclusion Criteria:
- Other primary or secondary systemic vasculitis
- Incapacity or refusal to sign the informed consent form
- Incapacity or refusal to adhere to treatment or perform the follow-up examinations required by the study
- Allergy, documented hypersensitivity or contraindication to the medications used in the present study (corticosteroids, rituximab)
- severe active infection
- Patient with severe heart failure (stage NYHA IV) or any other unstable heart disease Pregnancy, except for cases where the expected benefit oj treatment seems to surpass the potential risks
- Patients with active hepatitis B
- Any live vaccine within four weeks prior to the first infusion of RTX
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Rituximab
a classical induction regimen with rituximab (decision taken before inclusion), implying an infusion of 375mg/m² per week, for 4 consecutive weeks (from week -3 until week 0) with blood specimen.
|
blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
serum rituximab levels
Time Frame: 1 month after stop of rituximab induction regimen
|
rituximab level comparison between number of non-responders and number of responders after rituximab induction regimen.
The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0, 6 months after stop of induction regimen
|
1 month after stop of rituximab induction regimen
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
serum rituximab levels
Time Frame: 3 months after stop of rituximab induction regimen
|
rituximab level comparison between number of non-responders and number of responders after rituximab induction regimen.
The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen
|
3 months after stop of rituximab induction regimen
|
|
serum rituximab levels
Time Frame: 6 months after stop of rituximab induction regimen
|
rituximab level comparison between number of non-responders and number of responders after rituximab induction regimen.
The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen
|
6 months after stop of rituximab induction regimen
|
|
serum anti-rituximab antibodies
Time Frame: 1 month after stop of rituximab induction regimen
|
serum anti-rituximab antibodies level comparison between number of non-responders and number of responders after rituximab induction regimen.
The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen
|
1 month after stop of rituximab induction regimen
|
|
serum anti-rituximab antibodies
Time Frame: 3 months after stop of rituximab induction regimen
|
serum anti-rituximab antibodies level comparison between number of non-responders and number of responders after rituximab induction regimen.
The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen
|
3 months after stop of rituximab induction regimen
|
|
serum anti-rituximab antibodies
Time Frame: 6 months after stop of rituximab induction regimen
|
serum anti-rituximab antibodies level comparison between number of non-responders and number of responders after rituximab induction regimen.
The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen
|
6 months after stop of rituximab induction regimen
|
|
Serum B lymphocytes (CD19+ cells) levels
Time Frame: 1 month after stop of rituximab induction regimen
|
Serum B lymphocytes (CD19+ cells) levels comparison between number of non-responders and number of responders after rituximab induction regimen.
The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen
|
1 month after stop of rituximab induction regimen
|
|
Serum B lymphocytes (CD19+ cells) levels
Time Frame: 3 months after stop of rituximab induction regimen
|
Serum B lymphocytes (CD19+ cells) levels comparison between number of non-responders and number of responders after rituximab induction regimen.
The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen
|
3 months after stop of rituximab induction regimen
|
|
Serum B lymphocytes (CD19+ cells) levels
Time Frame: 6 months after stop of rituximab induction regimen
|
Serum B lymphocytes (CD19+ cells) levels comparison between number of non-responders and number of responders after rituximab induction regimen.
The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen
|
6 months after stop of rituximab induction regimen
|
|
patient number with adverse event
Time Frame: from start of induction rituximab regimen until six monthes after stop of induction regimen
|
frequency and nature of rituximab-attributed adverse events
|
from start of induction rituximab regimen until six monthes after stop of induction regimen
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Pascal CATHEBRAS, PHD, Chu Saint-Etienne
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Autoimmune Diseases
- Lung Diseases
- Lung Diseases, Interstitial
- Cerebral Small Vessel Diseases
- Systemic Vasculitis
- Vasculitis
- Granulomatosis with Polyangiitis
- Microscopic Polyangiitis
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Other Study ID Numbers
- 1508058
- 2015-001807-29 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.